Regular aspirin use among a sample of American Indians/Alaskan Natives in the Upper Midwest region of the United States

• Published in: Preventive medicine reports 2024-01, Vol.37, p.102571-102571, Article 102571
• Main Authors: Alabsi, Sarah M, Duval, Sue, Sundberg, Michael, Williams, Donovan, Luepker, Russell V, Eder, Milton, Van't Hof, Jeremy R
• Format: Article
• Language: English
• Subjects: Alaska Native; American Indian; Aspirin use; Preventive therapy; Provider communication; Underserved population
• ISSN: 2211-3355; 2211-3355
• DOI: 10.1016/j.pmedr.2023.102571

Despite high prevalence of cardiovascular disease (CVD) and CVD risk factors among American Indian or Alaska Native adults (AI/AN), there is little information on aspirin use in this population. This survey-based study seeks to understand prevalence of aspirin use in a sample of AI/AN adults in the Upper Midwestern United States. In-person and telephone based surveys were conducted querying self-reported CVD and CVD risk factors, aspirin use, and aspirin related discussion with clinicians. A total of 237 AI/AN participants were included: mean age (SD) was 60.8 (8.4) years; 143 (60 %) were women; 59 (25 %) reported CVD history. CVD risk factors were common particularly smoking (37 %) and diabetes (37 %). Aspirin use was much higher among those with CVD (secondary prevention, 76 %) than those without (primary prevention, 33 %). Primary prevention aspirin use was significantly associated with age and all CVD risk factors in unadjusted analyses. After adjustment for demographics and CVD risk factors, only age (aRR 1.13 per 5 years, 95 % CI 1.02, 1.25) and diabetes (aRR 2.44, 95 % CI 1.52, 3.92) remained significantly associated with aspirin. Regardless of CVD status, a higher proportion of those taking aspirin reported a conversation about aspirin with their doctor compared to those not taking aspirin. Among participants with no CVD, those who had such a conversation were 2.6 times more likely to use aspirin than those who did not have a conversation (aRR 2.64, 95 % CI 1.58, 4.44). The findings of this study emphasize the importance of the patient-provider relationship for preventive therapy.